華潤三九(000999.SZ):澳諾品牌下目前主要產品是葡萄糖酸鈣鋅口服溶液
格隆匯12月12日丨華潤三九(000999.SZ)於近期進行投資者關係活動,就“公司澳諾業務未來的增長驅動?”,公司回覆稱,澳諾品牌下目前主要產品是葡萄糖酸鈣鋅口服溶液。未來幾年澳諾業務仍有較好增長潛力:一是升級產品,將包裝更新換代為條袋裝;二是提升品牌,澳諾此前更多的是渠道品牌,公司希望將其打造成消費者品牌;三是拓展渠道,之前只在幾個省銷售,併購後在持續拓展新的市場和渠道,包括線上銷售比較好,增速快。四是計劃在澳諾品牌下持續引進和補充新品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.